Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter
  • 1-10 of  1,127 results for ""RITUXIMAB""

Your Filters

Subject : lymphoma, follicular Filter by : Subject
Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Lenalidomide, rituximab (R 2 ), and ixazomib for frontline treatment of high risk follicular and indolent non-Hodgkin lymphoma.

  • Authors : Hill BT; Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.; Chen Y

Subjects: Boron Compounds*/Boron Compounds*/Boron Compounds*/therapeutic use ; Boron Compounds*/Boron Compounds*/Boron Compounds*/administration & dosage ; Boron Compounds*/Boron Compounds*/Boron Compounds*/adverse effects

  • Source: Leukemia & lymphoma [Leuk Lymphoma] 2024 Jun; Vol. 65 (6), pp. 768-773. Date of Electronic Publication: 2024 Mar 08.Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

End-of-treatment 18[F]-FDG PET can predict early progression in patients receiving bendamustine-rituximab for follicular lymphoma in first relapse: a prospective West Japan hematology Study Group (W-JHS) NHL01 trial.

  • Authors : Kato K; Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, 3-1-1 Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan. .; Izutsu K

Subjects: Lymphoma, Follicular*/Lymphoma, Follicular*/Lymphoma, Follicular*/drug therapy ; Lymphoma, Follicular*/Lymphoma, Follicular*/Lymphoma, Follicular*/diagnostic imaging ; Lymphoma, Follicular*/Lymphoma, Follicular*/Lymphoma, Follicular*/mortality

  • Source: International journal of hematology [Int J Hematol] 2024 Jun; Vol. 119 (6), pp. 677-685. Date of Electronic Publication: 2024 Mar 22.Publisher: Springer Japan Country of Publication: Japan NLM ID: 9111627 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

A phase II Japanese trial of 90-minute rituximab infusion for untreated B-cell lymphoma.

  • Authors : Saito T; Department of Hematology/Cell Therapy, Aichi Cancer Center Hospital, 1-1, Kanokoden, Chikusa-ku, Nagoya-shi, Aichi 464-8681, Japan.; Nagai H

Subjects: Lymphoma, Follicular*/Lymphoma, Follicular*/Lymphoma, Follicular*/drug therapy ; Lymphoma, Large B-Cell, Diffuse*/Lymphoma, Large B-Cell, Diffuse*/Lymphoma, Large B-Cell, Diffuse*/drug therapy ; Lymphoma, Large B-Cell, Diffuse*/Lymphoma, Large B-Cell, Diffuse*/Lymphoma, Large B-Cell, Diffuse*/pathology

  • Source: Japanese journal of clinical oncology [Jpn J Clin Oncol] 2024 Apr 06; Vol. 54 (4), pp. 444-451.Publisher: Oxford University Press Country of Publication: England NLM ID: 0313225 Publication Model: Print Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Maintenance and consolidation strategies for patients with untreated advanced follicular lymphoma: A systematic review and network meta-analysis of randomized trials.

  • Authors : Chu Y; Department of Hematology, Shandong Provincial Hospital, Shandong University, Jinan, Shandong, China.; Liu Y

Subjects: Lymphoma, Follicular*/Lymphoma, Follicular*/Lymphoma, Follicular*/drug therapy ; Lymphoma, Follicular*/Lymphoma, Follicular*/Lymphoma, Follicular*/pathology; Humans

  • Source: Cancer [Cancer] 2024 Apr 01; Vol. 130 (7), pp. 1072-1082. Date of Electronic Publication: 2023 Dec 02.Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142

Record details

Read More Add to Saved list
×
Academic Journal

Risk factors of rituximab-induced thrombocytopenia in patients with autoimmune bullous diseases.

  • Authors : Lee SG; Department of Dermatology, Gangnam Severance Hospital, Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Korea.; Kim SC

Subjects: Thrombocytopenia*/Thrombocytopenia*/Thrombocytopenia*/chemically induced ; Thrombocytopenia*/Thrombocytopenia*/Thrombocytopenia*/epidemiology ; Lymphoma, Follicular*/Lymphoma, Follicular*/Lymphoma, Follicular*/drug therapy

  • Source: The Journal of dermatology [J Dermatol] 2024 Apr; Vol. 51 (4), pp. 597-601. Date of Electronic Publication: 2023 Oct 13.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 7600545 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Progression-free survival after front line, second line and third line in patients with follicular lymphoma treated in clinical practice.

  • Authors : Rajamaki A; Institute of Clinical Medicine, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland.; Sorigue M

Subjects: Lymphoma, Follicular*/Lymphoma, Follicular*/Lymphoma, Follicular*/mortality ; Lymphoma, Follicular*/Lymphoma, Follicular*/Lymphoma, Follicular*/drug therapy ; Lymphoma, Follicular*/Lymphoma, Follicular*/Lymphoma, Follicular*/therapy

  • Source: Acta oncologica (Stockholm, Sweden) [Acta Oncol] 2024 May 06; Vol. 63, pp. 267-272. Date of Electronic Publication: 2024 May 06.Publisher: Medical Journals Sweden AB Country of Publication: Sweden NLM ID: 8709065 Publication Model: Electronic Cited Medium: Internet ISSN:

Record details

Connect Read More Add to Saved list
×
Academic Journal

Analyzing the risk factors for disease progression within 2 years and histological transformation in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone as first-line treatment: A 15-year follow-up of patients with advanced follicular lymphoma in JCOG0203.

  • Authors : Watanabe T; Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.; Department of Personalized Control Science of Myeloid and Lymphoid Tumors, Mie University Graduate School of Medicine, Tsu, Japan.

Subjects: Lymphoma, Follicular*; Humans ; Rituximab/Rituximab/Rituximab/therapeutic use

  • Source: Hematological oncology [Hematol Oncol] 2024 May; Vol. 42 (3), pp. e3272.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 8307268 Publication Model: Print Cited Medium: Internet ISSN: 1099-1069

Record details

Read More Add to Saved list
×
Academic Journal

Follicular Lymphoma Presenting With Symptomatic Bone Involvement: A Clinicopathologic and Molecular Analysis of 16 Cases.

  • Authors : Sarro R; Institute of Pathology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and Lausanne University, Lausanne, Switzerland; Institute of Pathology Ente Ospedaliero Cantonale (EOC), Locarno, Switzerland.

Subjects: Lymphoma, Follicular*/Lymphoma, Follicular*/Lymphoma, Follicular*/genetics ; Lymphoma, Follicular*/Lymphoma, Follicular*/Lymphoma, Follicular*/therapy ; Lymphoma, Follicular*/Lymphoma, Follicular*/Lymphoma, Follicular*/pathology

  • Source: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc [Mod Pathol] 2024 Apr; Vol. 37 (4), pp. 100440. Date of Electronic Publication: Publisher: Elsevier Inc Country of Publication: United States NLM ID: 8806605 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Outcomes of the transformation of follicular lymphoma to diffuse large B-cell lymphoma in the rituximab era: A population-based study.

  • Authors : Zheng W; Department of Hematology, Hainan Hospital of Chinese PLA General Hospital, Sanya, China.; Liu M

Subjects: Lymphoma, Follicular*/Lymphoma, Follicular*/Lymphoma, Follicular*/drug therapy ; Lymphoma, Follicular*/Lymphoma, Follicular*/Lymphoma, Follicular*/epidemiology ; Hematopoietic Stem Cell Transplantation*

  • Source: Cancer medicine [Cancer Med] 2024 Apr; Vol. 13 (8), pp. e7120.Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study.

Subjects: Lymphoma, Follicular*/Lymphoma, Follicular*/Lymphoma, Follicular*/drug therapy ; Lymphoma, Follicular*/Lymphoma, Follicular*/Lymphoma, Follicular*/etiology ; Immunoconjugates*/Immunoconjugates*/Immunoconjugates*/adverse effects

  • Source: Haematologica [Haematologica] 2024 Apr 01; Vol. 109 (4), pp. 1194-1205. Date of Electronic Publication: 2024 Apr 01.Publisher: Ferrata Storti Foundation Country of Publication: Italy NLM ID: 0417435 Publication Model: Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
  • 1-10 of  1,127 results for ""RITUXIMAB""